These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1010 related articles for article (PubMed ID: 21609657)

  • 1. Golimumab for the treatment of psoriatic arthritis.
    Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
    Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.
    Yang H; Craig D; Epstein D; Bojke L; Light K; Bruce IN; Sculpher M; Woolacott N
    Pharmacoeconomics; 2012 Apr; 30(4):257-70. PubMed ID: 22283690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Rodgers M; Epstein D; Bojke L; Yang H; Craig D; Fonseca T; Myers L; Bruce I; Chalmers R; Bujkiewicz S; Lai M; Cooper N; Abrams K; Spiegelhalter D; Sutton A; Sculpher M; Woolacott N
    Health Technol Assess; 2011 Feb; 15(10):i-xxi, 1-329. PubMed ID: 21333232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence.
    O'Connor J; Rice S; Smith A; Rodgers M; Lopez RR; Craig D; Woolacott N
    Pharmacoeconomics; 2016 Apr; 34(4):337-48. PubMed ID: 26818809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.
    Bravo Vergel Y; Hawkins NS; Claxton K; Asseburg C; Palmer S; Woolacott N; Bruce IN; Sculpher MJ
    Rheumatology (Oxford); 2007 Nov; 46(11):1729-35. PubMed ID: 17956918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal.
    Armstrong N; Joore M; van Asselt T; Misso K; Manning N; Tomini F; Kleijnen J; Riemsma R
    Pharmacoeconomics; 2013 May; 31(5):415-25. PubMed ID: 23580355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF-alpha inhibitors for ankylosing spondylitis.
    Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD005468. PubMed ID: 25887212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-efficacy of biologic therapies for psoriatic arthritis from the perspective of the Taiwanese healthcare system.
    Yang TS; Chi CC; Wang SH; Lin JC; Lin KM
    Int J Rheum Dis; 2016 Oct; 19(10):1002-1009. PubMed ID: 26404916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis.
    Cummins E; Asseburg C; Punekar YS; Shore E; Morris J; Briggs A; Fenwick E
    Value Health; 2011 Jan; 14(1):15-23. PubMed ID: 21211482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of golimumab for the treatment of active psoriatic arthritis.
    Cummins E; Asseburg C; Prasad M; Buchanan J; Punekar YS
    Eur J Health Econ; 2012 Dec; 13(6):801-9. PubMed ID: 21720868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
    J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ustekinumab for the treatment of moderate to severe psoriasis.
    Gospodarevskaya E; Picot J; Cooper K; Loveman E; Takeda A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():61-6. PubMed ID: 19846031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab for the treatment of adults with psoriasis.
    Loveman E; Turner D; Hartwell D; Cooper K; Clegg A
    Health Technol Assess; 2009 Jun; 13 Suppl 1():55-60. PubMed ID: 19567215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab for the treatment of rheumatoid arthritis.
    Bagust A; Boland A; Hockenhull J; Fleeman N; Greenhalgh J; Dundar Y; Proudlove C; Kennedy T; Moots R; Williamson P; Dickson R
    Health Technol Assess; 2009 Sep; 13 Suppl 2():23-9. PubMed ID: 19804686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective.
    Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G
    Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
    Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
    Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.